MC1AVR1 Micra AV
Transcatheter Pacing System (TPS)
MC1AVR1 Micra AV
Information

Device Survival Probability

MC1AVR1_SURV
Loading...










    1 yr 2 yr at 26.0 mo              
% Excluding Normal Battery Depletion 99.9 99.8 99.8              
% Including Normal Battery Depletion 99.8 99.5 99.5              
#   4814 333 105              
  • Including Normal Battery Depletion – This curve includes devices that have reached at least 80% of expected longevity. This curve is most representative of clinical performance and how long the device will last.
  • Excluding Normal Battery Depletion – This is the malfunction free survival curve.
Information

Customer Communications For This Model

Information

Product Characteristics

Generator Type TPS
NBD Code VDD
Max. Delivered Energy N/A
More
Serial Number Prefix MAV
Mass 1.75 g
Volume 1 cc
Waveform N/A
X-Ray ID Medtronic Logo
Hide this content
Information

CareLink Population

Enrolled 12305
Active 11027
Cumulative Follow-Up Months 126587
Normal Battery Depletion 8
Information 11

CareLink Qualifying Malfunctions/Complications

Dislodgements 1
Elevated Pacing Threshold 5
Failure to Capture 4
Premature Battery Depletion 1
Information

Distribution Data

US Market Release2020-01-15
CE Approval Date2020-03-31
Registered USA Implants26811
US Market Release2020-01-15
CE Approval Date2020-03-31
Estimated WW Distribution40386
Information

*Acute Observations (N = 26811)

Cardiac Perforation9
Dislodgement13
Elevated Pacing Threshold38
Failure to Capture17
Failure to Sense77
Information

*Day of Implant Observations (N = 26811)

Cardiac Perforation166
Dislodgement42
Elevated Pacing Threshold78
Failure to Capture46
Failure to Sense18

The rate of perforation for commercially released Micra AV devices continues to perform acceptably within levels observed within the post-approval clinical study registry. Overall, predicate clinical studies for Micra VR have demonstrated a reduction in the risk of major complications of 63% through 12 months1 and 57% through 36 months2 relative to transvenous pacing systems.

Information

EOL Indicator

From the point that the RRT is set, the pacemaker will operate for approximately six months for typical pacemaker configurations during the normal operating life.

Information

Recommended Replacement (RRT)

6 months before battery voltage measures less than or equal to 2.5V on 3 consecutive daily automatic measurements.

Information

Estimated Longevity

Amplitude Setting 500 Lead Ω 700 Lead Ω
Low 1.0 V 12.1 12.8
Nominal 2.0 V 7.8 9.1
High 2.5 V 6.4 7.6
Footnote

Longevity estimates based on the following device usage. Pace/Sense Mode VVIR Right Ventricle Pulse Width 0.24 ms; Lower Pace Rate 60 bpm; Right Ventricle Percent Paced 100 %; Upper Sensing Rate 130 ppm; VCM Mode: Adaptive, 0.5, 1.5 Acute PSF, 0.5 PSFHide this content

1. El-Chami et al. Heart Rhythm 2018 15(12): 1800-1807.
2. Piccini et al. Heart Rhythm 2020 17(5 Supplement) D-PO02-089
* Data in these tables is sourced direct from the MDT complaint handling database summarizing observations reported to Medtronic relative to the registered US implant population.

Data as of July 27, 2022

www.medtronic.com/productperformance 876050